Lilly takes on Pfizer.

Lilly takes on Pfizer, Novartis with new breast cancer drug data NEW YORK/MADRID – Eli Lilly staked its state for the slice of product sales in a fresh class of breasts cancer drugs about Sunday as scientific data showed adding its medicine abemaciclib to regular therapy reduced the chance of disease development by 46 %. Adding abemaciclib to standard endocrine therapy resulted in significant tumour shrinkage in 59 % of individuals weighed against 44 % in those on endocrine medicines alone in the ongoing research dubbed Monarch-3.7 months before disease worsening . Insufficient patients about abemaciclib had seen their disease worsen after 1.